Evidence item

The passage directly reports the treated and placebo counts, cross-resistance, and retained activity of N6 and 1–18. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 18852

Source: Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials · locator {} · excerpt hash sha256:e683af390d31c68f37a1379fb706066e6369c09bdcd21692933e886934d52c27

Exact excerpt

Here we analysed 11,730 HIV envelope sequences generated during the AMP trials from 47 participants, identifying VRC01-mediated de novo escape mutations in 8 of 26 VRC01-treated participants but none in 21 placebo participants. ... Escape mutations ... conferred cross-resistance to several CD4bs bnAbs; however, more potent CD4bs bnAbs such as N6 and 1–18 largely retained their activity.

Linked claims

Claim	Direction	Relevance	Steps	Counted
fc4c6343	SUPPORT	DIRECT	0	yes

Audits

None.